Anti-PCSK9 [FAP2M21]

Catalogue Number: AB02936-23.0-BT-ABA

Manufacturer:Vector Laboratories, Inc (ABA)
Type:Recombinant Monoclonal
Alias:NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
Shipping Condition:Blue Ice
Unit(s): 1 mg
Host name: Rabbit
Clone: FAP2M21
Isotype: IgG
Immunogen: The original antibody was generated by panning a fully human scFv phage display library with recombinant human PCSK9. Later on the scFv was transformed into a full length IgG antibody.
Application: ELISA, FC, IF, FA, Blk, Inh

Additional Text

Uniprot ID

Q8NBP7

Gene Name

PCSK9

Gene ID

255738

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.

Application Notes

This antibody binds human PCSK9 with an extremely slow dissociation rate constant and exert its hypolipidemic effect by blocking PCSK9-LDLR interaction. The binding characterization of this antibody was done using ELISA. Bio-Layer Interferometry (BLI) analysis revealed that the full-length IgG1 antibody FAP2M21 binds to hPCSK9 with a KD as low as 1.42 nM, and a dramatically slow dissociation rate (koff, 4.68 x 10-6 s-1) (PMID: 33647772). This antibody was also used to analyze LDLR expressed on the surface of HepG2 cells using flow cytometry and immunofluorescence staining. This antibody potently inhibited PCSK9-induced reduction of LDL-C uptake in HepG2 cells, with an EC50 of 43.56 nM. When this antibody was injected in C57BL/6 mice expressing human PCSK9, it dose-dependently up-regulated hepatic LDLR levels, and concomitantly reduced serum LDL-C by 3.3% and 37.2%, respectively (PMID: 33647772).

Short Description

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.